These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20169304)

  • 1. Paradoxical reactions to targeted biological treatments: A way to treat and trigger?
    Brunasso AM; Laimer M; Massone C
    Acta Derm Venereol; 2010 Mar; 90(2):183-5. PubMed ID: 20169304
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept.
    Brigant F; Clavel G; Chatelain D; Lok C; Chaby G
    Dermatol Online J; 2011 Jun; 17(6):11. PubMed ID: 21696691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoriasiform and pustular eruption induced by etanercept and infliximab.
    Kuhara T; Watanabe D; Iwahori Y; Tamada Y; Yamamura M; Matsumoto Y
    Eur J Dermatol; 2009; 19(4):388-9. PubMed ID: 19467963
    [No Abstract]   [Full Text] [Related]  

  • 4. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis.
    Kowalzick L; Bertolini J; Baumann C; Walther B; Truhm B; Eickenscheidt L
    J Dtsch Dermatol Ges; 2013 May; 11(5):447-9. PubMed ID: 23343137
    [No Abstract]   [Full Text] [Related]  

  • 5. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.
    Vandevyvere K; Luyten FP; Verschueren P; Lories R; Segaert S; Westhovens R
    Clin Rheumatol; 2007 Dec; 26(12):2205-2206. PubMed ID: 17876646
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyoderma gangrenosum possibly triggered by adalimumab.
    Kikuchi N; Hiraiwa T; Ohashi T; Hanami Y; Satoh M; Takenoshita H; Yamamoto T
    Eur J Dermatol; 2012; 22(6):804-5. PubMed ID: 23107608
    [No Abstract]   [Full Text] [Related]  

  • 8. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
    Siddiqui MA
    Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor necrosis factor-alpha-induced psoriasis.
    Sari I; Akar S; Birlik M; Sis B; Onen F; Akkoc N
    J Rheumatol; 2006 Jul; 33(7):1411-4. PubMed ID: 16821276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New-onset psoriasis associated with etanercept therapy.
    Chen LA; Su LH; Chang YJ; Hsu YL; Tsai TH
    J Dermatol; 2010 Apr; 37(4):378-80. PubMed ID: 20507411
    [No Abstract]   [Full Text] [Related]  

  • 11. Abatacept-induced psoriasis.
    Silverman D; Oliver A
    Cutis; 2011 Sep; 88(3):117-8. PubMed ID: 22017062
    [No Abstract]   [Full Text] [Related]  

  • 12. A Case of Pyoderma Gangrenosum in a Patient with Rheumatoid Arthritis Treated with Abatacept.
    Akahoshi-Ikeda M; Yoshizawa S; Motoshita J; Furue M; Takeuchi S
    Acta Derm Venereol; 2016 Aug; 96(6):822-3. PubMed ID: 26912455
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis.
    Tada M; Nakanishi T; Hirata C; Okano T; Sugioka Y; Wakitani S; Nakamura H; Koike T
    Mod Rheumatol; 2010 Dec; 20(6):598-601. PubMed ID: 20680379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases.
    Dereure O; Guillot B; Jorgensen C; Cohen JD; Combes B; Guilhou JJ
    Br J Dermatol; 2004 Aug; 151(2):506-7. PubMed ID: 15327565
    [No Abstract]   [Full Text] [Related]  

  • 15. [Biological agents].
    Amano K
    Nihon Rinsho; 2009 Mar; 67(3):593-8. PubMed ID: 19280938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists.
    Kary S; Worm M; Audring H; Huscher D; Renelt M; Sörensen H; Ständer E; Maass U; Lee H; Sterry W; Burmester GR
    Ann Rheum Dis; 2006 Mar; 65(3):405-7. PubMed ID: 16150791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifocal pyoderma gangrenosum resistant to infliximab in active ulcerative colitis: don't forget the role of cyclosporin.
    Sinagra E; Orlando A; Renna S; Maida M; Cottone M
    Inflamm Bowel Dis; 2012 Aug; 18(8):E1594-5. PubMed ID: 22038892
    [No Abstract]   [Full Text] [Related]  

  • 20. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon?
    Stichenwirth M; Riedl E; Pehamberger H; Tappeiner G
    Arch Dermatol; 2008 Jun; 144(6):817-8. PubMed ID: 18559788
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.